Michael Postow
Scientist
Ludwig Center at MSKÂ
Ludwig Institute for Cancer Research
United States of America
Biography
I am part of the Melanoma-Sarcoma Oncology Service. I have an interest in developing clinical trials involving immunotherapeutic strategies for patients with melanoma. My specific areas of interest include studying the immunologic effects of radiotherapy and characterizing pharmacodynamic biomarkers associated with ipilimumab outcomes. I plan to continue bridging basic laboratory advances with novel clinical observations to improve the care of our patients.
Research Interest
Melanoma-Sarcoma, radiotherapy, pharmacodynamic biomarkers
Publications
-
Snyder, Alexandra, et al. "Genetic basis for clinical response to CTLA-4 blockade in melanoma." New England Journal of Medicine 371.23 (2014): 2189-2199.
-
Larkin, James, et al. "Combined nivolumab and ipilimumab or monotherapy in untreated melanoma." New England journal of medicine 373.1 (2015): 23-34.
-
Wolchok, Jedd D., et al. "Nivolumab plus ipilimumab in advanced melanoma." New England Journal of Medicine 369.2 (2013): 122-133.
